Kabra Drugs share news, announcements and annual reports
BSE: 524322Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹15.72.
30 Oct: open ₹15.99, high ₹16.49, low ₹15.67
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹39 Cr3,225th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 5.11
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.31
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 28.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 28.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 59,920
Kabra Drugs share news and announcements
558 announcements, routine notices left out, newest first. Page 5 of 12.
Nov 2022
Oct 2022
27 Oct · Board meeting
Meeting on 2 Nov 20227 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2022
30 Sep · Meeting
22 Sep · Reg. 34 (1) Annual Report.
Aug 2022
26 Aug · Board meeting
Meeting on 2 Sep 20228 Aug · Board meeting
Meeting on 13 Aug 2022: quarterly results
Jul 2022
15 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 07 Jul · Board meeting
Meeting on 14 Jul 2022
Jun 2022
3 Jun · Board meeting
Meeting on 9 Jun 20222 Jun · Subject: Compliance Certificate Pursuant To Regulation 40(9) And 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2022
May 2022
30 May · Submission Of Half Yearly Disclosure On Related Party Transactions.
23 May · Board meeting
Meeting on 30 May 2022: audited results and quarterly results
Apr 2022
30 Apr · Compliance Certificate Pursuant To Regulation 40(9) And 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2022
29 Apr · Board meeting
Meeting on 6 May 20228 Apr · Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR), Regulations 2015
8 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Mar 2022
14 Mar · Board meeting
Meeting on 18 Mar 2022